Andrew Lloyd

19.7k total citations · 3 hit papers
175 papers, 13.2k citations indexed

About

Andrew Lloyd is a scholar working on Economics and Econometrics, General Health Professions and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Andrew Lloyd has authored 175 papers receiving a total of 13.2k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Economics and Econometrics, 25 papers in General Health Professions and 21 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Andrew Lloyd's work include Health Systems, Economic Evaluations, Quality of Life (75 papers), Economic and Environmental Valuation (14 papers) and Economic and Financial Impacts of Cancer (12 papers). Andrew Lloyd is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (75 papers), Economic and Environmental Valuation (14 papers) and Economic and Financial Impacts of Cancer (12 papers). Andrew Lloyd collaborates with scholars based in United Kingdom, United States and Switzerland. Andrew Lloyd's co-authors include Paul Kind, Michael Herdman, Xavier Badı́a, M.H.M. Janssen, Gouke J. Bonsel, Claire Gudex, David Parkin, A. Simon Pickard, Lisa A. Prosser and John F. P. Bridges and has published in prestigious journals such as Journal of Clinical Oncology, Social Science & Medicine and British Journal of Cancer.

In The Last Decade

Andrew Lloyd

162 papers receiving 13.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)

2011 6.1k citations Michael Herdman, Claire Gudex et al. Quality of Life Research profile →
Conjoint Analysis Applications in Health—a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force

2011 1.4k citations Andrew Lloyd, Lisa A. Prosser et al. Value in Health profile →
Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets

2012 1.4k citations Andrew Lloyd, Paul Kind et al. Value in Health profile →

Peers

Countries citing papers authored by Andrew Lloyd

Since Specialization

Citations

This map shows the geographic impact of Andrew Lloyd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Lloyd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Lloyd more than expected).

Fields of papers citing papers by Andrew Lloyd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Lloyd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Lloyd. The network helps show where Andrew Lloyd may publish in the future.

Co-authorship network of co-authors of Andrew Lloyd

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Lloyd. A scholar is included among the top collaborators of Andrew Lloyd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Lloyd. Andrew Lloyd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Burden of Adult X-Linked Hypophosphatemia on Carers and Family Members: A Mixed-Methods Study 2025 ·Journal of health economics and outcomes research ·E. Ann Matter, (unknown), (unknown), Victoria Hayes, Gemma E. Logan, B. Johnson, Andrew Lloyd	0
2	Uncertainty around Health State Values Used in Cost-Effectiveness Analysis: How It Arises and How to Deal with It 2025 ·Medical Decision Making ·David Parkin, Andrew Briggs, (unknown), Andrew Lloyd, (unknown)	0
3	Estimating health state utilities for aromatic L-amino acid decarboxylase deficiency (AADCd) in the United States 2025 ·Health and Quality of Life Outcomes ·(unknown), (unknown), Gin Nie Chua, Rongrong Zhang, Andrew Lloyd, Paul Castellano, Ioannis Tomazos	0
4	Living with and Caring for People with Multiple Food Allergies: A Qualitative Study 2024 ·Patient Preference and Adherence ·Christina E. Ciaccio, J W Dunne, (unknown), Karissa Johnston, Stacey Kowal, (unknown), Andrew Lloyd, (unknown)	4
5	LBA19 Capivasertib (C) + paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial 2024 ·Annals of Oncology ·Peter Schmid, Heather L. McArthur, (unknown), Baojun Xu, (unknown), (unknown), Utkan Demirci, (unknown), Jaya Ghosh, Roberto Hegg, Hiroaki Iwata, Yamil Alonso Lopez Chuken, M. Nechaeva, Mark E. Robson, Ricardo Villalobos-Valencia, Andrew Lloyd, Celina M. D’Cruz, Andrew Foxley, Y.H. Park	5
6	Recommendations for Emerging Good Practice and Future Research in Relation to Family and Caregiver Health Spillovers in Health Economic Evaluations: A Report of the SHEER Task Force 2023 ·PharmacoEconomics ·(unknown), Hareth Al‐Janabi, Werner Brouwer, John Cullinan, Lidia Engel, Susan Griffin, Claire Hulme, Pritaporn Kingkaew, Andrew Lloyd, Nalin Payakachat, Becky Pennington, Luz María Peña-Longobardo, Lisa A. Prosser, Koonal Shah, Wendy J. Ungar, Thomas Wilkinson, Eve Wittenberg	17
7	Societal Utilities for Cognitive Impairment in Schizophrenia: Developing a Preference-Based Scoring Algorithm Based on the Schizophrenia Cognition Rating Scale 2023 ·Advances in Therapy ·Irene Santi, Andrew Lloyd, Claudia Hastedt, Matthijs Versteegh	1
8	Patient-reported outcome measures in MS: Do development processes and patient involvement support valid quantification of clinically important variables? 2022 ·Multiple Sclerosis Journal - Experimental Translational and Clinical ·(unknown), (unknown), Tanuja Chitnis, (unknown), Birgit Bauer, Giampaolo Brichetto, Andrew Lloyd, Hollie Schmidt, (unknown), Jennifer Fitzgerald, Thomas Hach, Jeremy Hobart	6
9	Patient and Caregiver Health State Utilities in Tuberous Sclerosis Complex 2021 ·PharmacoEconomics - Open ·Siu Hing Lo, J.D. Marshall, (unknown), Andrew Lloyd	6
10	Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom 2021 ·PharmacoEconomics ·Siu Hing Lo, Ksenija Gorni, C. Simone Sutherland, (unknown), Andrew Lloyd, Noman Paracha	7
11	Time Trade-Off Utilities for Hereditary Angioedema Health and Caregiver States 2021 ·PharmacoEconomics - Open ·Siu Hing Lo, Andrew Lloyd, Shuayb Elkhalifa, Zlatko Sisic, Floortje van Nooten	2
12	Patient and Caregiver Treatment Preferences in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy: A Discrete Choice Experiment Survey in Five European Countries 2021 ·PharmacoEconomics ·Siu Hing Lo, (unknown), (unknown), (unknown), Andrew Lloyd	5
13	Patient Preferences for Advanced Hepatocellular Carcinoma Treatment: A Multicountry Stated Preference Study 2021 ·Future Oncology ·Siu Hing Lo, Rohini Sharma, Charlotte Costentin, Daniel Aggio, (unknown), (unknown), Victoria K. Brennan, (unknown), Ion Agirrezabal, Andrew Lloyd	16
14	Managing neurogenic bowel dysfunction: what do patients prefer? A discrete choice experiment of patient preferences for transanal irrigation and standard bowel management 2016 ·Patient Preference and Adherence ·Beenish Nafees, Andrew Lloyd, Anton Emmanuel, Rachel Ballinger	10
15	Utilities for advanced basal cell carcinoma 2013 ·Journal of Medical Economics ·S.L. Shingler, (unknown), (unknown), John T. Lear, Stephen Keohane, Andrew Lloyd	15
16	Comparative Analysis Of Radium-223 Versus Placebo In Symptomatic Metastatic Castration Resistant Prostate Cancer Treated With Best Standard Of Care On Skeletal-Related Events Outcomes 2013 ·Value in Health ·Brian Seal, (unknown), Adriana Valderrama, (unknown), Andrew Lloyd, Amélie Beaudet	1
17	Drivers Of Cost-Effectiveness In Type-2 Diabetes Mellitus 2013 ·Value in Health ·Phil McEwan, V. Foos, (unknown), Mark Lamotte, James L. Palmer, Andrew Lloyd	0
18	Assessing The Consistency Of Absolute Cardiovascular Risk Prediction And Relative Risk Reduction In Type-2 Diabetes Mellitus 2013 ·Value in Health ·Phil McEwan, Mark Lamotte, (unknown), James L. Palmer, Andrew Lloyd, V. Foos	0
19	Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) breakdown → 2011 ·Quality of Life Research ·Michael Herdman, Claire Gudex, Andrew Lloyd, M.H.M. Janssen, Paul Kind, David Parkin, Gouke J. Bonsel, Xavier Badı́a	6138
20	An Investigation into the Use of Aromatherapy in Intrapartum Midwifery Practice 2000 ·The Journal of Alternative and Complementary Medicine ·Ethel Burns, (unknown), Steven Ersser, L. Barnetson, Andrew Lloyd	69

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact